Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Standardizing 3D Tumor Spheroid Assays for Glioblastoma Stem
2026-05-20
This study introduces a streamlined 3D-tumor spheroid assay to functionally assess the stemness of glioblastoma cell lines. The protocol enhances reproducibility, reduces time and resources, and is well-suited for high-throughput screening and mechanistic studies in glioma research.
-
Machine Learning Uncovers Novel Senolytics for Senescent Cel
2026-05-19
The reference study demonstrates the use of cost-effective machine learning algorithms to identify new senolytic compounds capable of selectively eliminating senescent cells. This approach substantially reduces screening costs and opens new avenues for targeted therapies in cancer and age-related diseases.
-
SU 5402 (SKU A3843): Data-Backed Solutions for Cell-Based As
2026-05-19
This article provides an evidence-based, scenario-driven exploration of SU 5402 (SKU A3843), focusing on its reliability and performance in cell viability, proliferation, and apoptosis assays. Drawing on published literature and real laboratory challenges, it guides biomedical researchers and technicians on optimizing protocols and vendor selection for reproducible tyrosine kinase inhibition studies.
-
Carboxylesterase Interference in Mitochondrial H2O2 Assays:
2026-05-18
Miwa et al. (2016) demonstrate that carboxylesterases can directly convert Amplex Red to resorufin independently of hydrogen peroxide, distorting mitochondrial H2O2 release measurements. This work urges re-evaluation of widely used ROS detection protocols and provides corrective strategies to enhance assay specificity.
-
Moxidectin: Macrocyclic Lactone Anthelmintic in Antifungal M
2026-05-18
Moxidectin, a macrocyclic lactone anthelmintic, is emerging as a pivotal agent not only for parasitic worm control in veterinary medicine but also as a powerful enhancer of polyene antifungal efficacy. This article decodes practical workflows, protocol refinements, and troubleshooting tips for leveraging high-purity moxidectin from APExBIO in translational research on Candida albicans and beyond.
-
SAG: Smoothened Receptor Agonist for Advanced Assay Design
2026-05-17
Smoothened Agonist (SAG) unlocks precise Hedgehog pathway activation for mitochondrial, neuroprotection, and developmental models. This guide delivers actionable workflows, protocol parameters, and troubleshooting strategies, translating recent research into robust, reproducible lab results.
-
Y-27632 Dihydrochloride: Applied ROCK Inhibitor Workflows &
2026-05-16
Y-27632 dihydrochloride stands apart as a highly selective ROCK inhibitor, enabling reproducible modulation of Rho/ROCK signaling for cytoskeletal, stem cell, and cancer research. This article unpacks experimental workflows, protocol upgrades, and troubleshooting strategies to help you maximize data quality and biological insight.
-
NSC 87877: Applied Workflows for Shp2 Inhibitor Research
2026-05-15
NSC 87877 stands out as a benchmark Shp2 inhibitor, enabling precise interrogation of Shp2-driven neuroinflammatory and oncogenic signaling pathways. This article delivers actionable workflow enhancements, troubleshooting guides, and protocol parameters, drawing from the latest mechanistic insights and landmark studies.
-
Erlotinib (NSC 718781): Precision EGFR Inhibition in the Era
2026-05-15
Explore the advanced use of Erlotinib (NSC 718781) as a potent EGFR inhibitor in cancer research. This article uniquely bridges molecular assay design with emerging insights into SCUBE3-mediated resistance, offering scientists actionable strategies for robust, next-generation experimental workflows.
-
Erlotinib (NSC 718781): Optimizing EGFR Signaling Inhibition
2026-05-14
Erlotinib (NSC 718781) delivers highly selective, quantitative EGFR autophosphorylation inhibition, empowering researchers to dissect oncogenic signaling. This article unpacks workflow advances, troubleshooting insights, and new directions inspired by the latest research on SCUBE3-driven resistance.
-
Norovirus Hijacks NINJ1 for Selective Viral Protein Secretio
2026-05-14
This study uncovers how murine norovirus exploits the host membrane protein NINJ1 to selectively secrete its NS1 protein during infection. The findings reveal a unique, caspase-3–dependent mechanism of unconventional protein export, with implications for understanding regulated cell death and host-pathogen interactions.
-
ERK Inhibition Reduces Mitochondrial Fragmentation in OGD/R
2026-05-13
Yuan et al. reveal that ERK inhibition protects neuronal cells from oxygen-glucose deprivation/reoxygenation (OGD/R) injury by downregulating autophagy and mitigating mitochondrial fragmentation. This mechanistic insight clarifies the ERK-Drp1/Mfn2-autophagy axis in cerebral ischemia-reperfusion injury and suggests new avenues for neuroprotection.
-
5-Azacytidine: Dormancy Induction and Metastasis Suppression
2026-05-13
Explore how 5-Azacytidine (5-AzaC) functions as a DNA demethylation agent, not only reactivating silenced genes but also inducing cancer cell dormancy to suppress metastasis. This article uniquely translates recent mechanistic insights into actionable assay strategies for advanced oncology research.
-
BMS 599626: Mechanistic Precision for Translational Oncology
2026-05-12
Explore how BMS 599626 dihydrochloride, a highly selective EGFR and ErbB2 inhibitor, delivers mechanistic clarity and strategic advantage for translational researchers. This article bridges robust experimental rationale, competitive intelligence, and recent advances in senescence and AI-driven drug discovery, guiding the next wave of breakthroughs in breast and lung cancer models.
-
Oltipraz for MASLD Models: Beyond Nrf2 to Autophagy and Ferr
2026-05-12
Explore how Oltipraz, a potent Nrf2 activator, uniquely enables MASLD and liver disease research by bridging detoxification, autophagy, and ferroptosis pathways. Discover nuanced assay protocols and evidence-based insights distinct from standard chemoprevention workflows.